Q-702 is under clinical development by Qurient and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II drugs for Gastric Cancer have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Q-702’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Q-702 is under development for the treatment of advanced solid tumors including esophageal cancer, gastric cancer, cervical cancer, hepatocellular carcinoma, gastroesophageal (GE) junction carcinomas, metastatic hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC) and acute myeloid leukemia. It is administered through oral route. The drug candidate acts by targeting Axl, Mer and CSF1 receptor tyrosine kinases.
Qurient is a biotechnology company. It develops drugs for unmet medical needs of atopic diseases and cancer. The company offers pipeline products that include Q301, a topical leukotriene inhibitor for the treatment of atopic dermatitis; Telacebec (Q203), a Cyt bc1 Inhibitor for combating mycobacterium associated tuberculosis infection; and Q702, an Axl/Mer/CSF1R triple kinase inhibitor for the treatment of drug resistant non-small cell lung cancer and other cancer types. Qurient in-licensed Q702 from Max Planck Innovation and Lead Discovery Center. It is also advancing its pre-clinical pipeline that includes a topical 5-lipoxygenase inhibitor to treat allergic and atopic diseases; and selective CDK7 inhibitors to treat cancer. Qurient is headquartered in Seongnam, Gyeonggi, South Korea.
For a complete picture of Q-702’s drug-specific PTSR and LoA scores, buy the report here.